Literature DB >> 28887186

To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis.

R B Dessau1, A P van Dam2, V Fingerle3, J Gray4, J W Hovius5, K-P Hunfeld6, B Jaulhac7, O Kahl8, W Kristoferitsch9, P-E Lindgren10, M Markowicz11, S Mavin12, K Ornstein13, T Rupprecht14, G Stanek11, F Strle15.   

Abstract

BACKGROUND: Lyme borreliosis (LB) is a tick-borne infection caused by Borrelia burgdorferi sensu lato. The most frequent clinical manifestations are erythema migrans and Lyme neuroborreliosis. Currently, a large volume of diagnostic testing for LB is reported, whereas the incidence of clinically relevant disease manifestations is low. This indicates overuse of diagnostic testing for LB with implications for patient care and cost-effective health management. AIM: The recommendations provided in this review are intended to support both the clinical diagnosis and initiatives for a more rational use of laboratory testing in patients with clinically suspected LB. SOURCES: This is a narrative review combining various aspects of the clinical and laboratory diagnosis with an educational purpose. The literature search was based on existing systematic reviews, national and international guidelines and supplemented with specific citations. IMPLICATIONS: The main recommendations according to current European case definitions for LB are as follows. Typical erythema migrans should be diagnosed clinically and does not require laboratory testing. The diagnosis of Lyme neuroborreliosis requires laboratory investigation of the spinal fluid including intrathecal antibody production, and the remaining disease manifestations require testing for serum antibodies to B. burgdorferi. Testing individuals with non-specific subjective symptoms is not recommended, because of a low positive predictive value.
Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. All rights reserved.

Entities:  

Keywords:  Antibody testing; Borrelia burgdorferi; Laboratory diagnosis; Lyme borreliosis; Polymerase chain reaction; Serology

Mesh:

Substances:

Year:  2017        PMID: 28887186     DOI: 10.1016/j.cmi.2017.08.025

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  28 in total

1.  Association of Seropositivity to Borrelia burgdorferi With the Risk of Neuropsychiatric Disorders and Functional Decline in Older Adults: The Aging Multidisciplinary Investigation Study.

Authors:  Virgilio Hernández Ruiz; Arlette Edjolo; Claire Roubaud-Baudron; Benoît Jaulhac; José-Alberto Avila-Funes; Jean-François Dartigues; Hélène Amieva; Karine Pérès
Journal:  JAMA Neurol       Date:  2020-02-01       Impact factor: 18.302

2.  The French Society of Internal Medicine's Top-5 List of Recommendations: a National Web-Based Survey.

Authors:  Nathan Peiffer-Smadja; Adeline Bauvois; Marie Chilles; Baptiste Gramont; Redwan Maatoug; Marie Bismut; Camille Thorey; Eric Oziol; Thomas Hanslik
Journal:  J Gen Intern Med       Date:  2019-06-12       Impact factor: 5.128

3.  The Performance of Nine Commercial Serological Screening Assays for the Diagnosis of Lyme Borreliosis: a Multicenter Modified Two-Gate Design Study.

Authors:  B J A Hoeve-Bakker; Mark Jonker; Afke H Brandenburg; P Martijn den Reijer; Foekje F Stelma; Alje P van Dam; Tamara van Gorkom; Karen Kerkhof; Steven F T Thijsen; Kristin Kremer
Journal:  Microbiol Spectr       Date:  2022-03-17

4.  Borrelia burgdorferi Is a Poor Inducer of Gamma Interferon: Amplification Induced by Interleukin-12.

Authors:  Frederik R van de Schoor; Hedwig D Vrijmoeth; Michelle A E Brouwer; Hadewych J M Ter Hofstede; Heidi L M Lemmers; Helga Dijkstra; Collins K Boahen; Marije Oosting; Bart-Jan Kullberg; Joppe W Hovius; Cees C van den Wijngaard; Frank L van de Veerdonk; Mihai G Netea; Leo A B Joosten
Journal:  Infect Immun       Date:  2022-02-07       Impact factor: 3.609

5.  Spirochetal uveitis: Spectrum of clinical manifestations, diagnostic and therapeutic approach, final outcome and epidemiological data.

Authors:  Dimitrios Kalogeropoulos; Ioannis Asproudis; Maria Stefaniotou; Marilita Moschos; Constantina Gartzonika; Ioannis Bassukas; Spiros Konitsiotis; Haralampos Milionis; Georgios Gaitanis; Konstantinos Malamos; Chris Kalogeropoulos
Journal:  Int Ophthalmol       Date:  2021-07-23       Impact factor: 2.031

6.  Lyme disease and heart transplantation: presentation of a clinical case and a literature review.

Authors:  Audrius Aurelijus Pilypas; Giedrutė Raišelienė; Jurgita Valaikienė
Journal:  Acta Med Litu       Date:  2019

7.  Diagnostic Performance of the Novel BioPlex Lyme Serological Assays in European Patients with Lyme Disease.

Authors:  M E (Ewoud) Baarsma; Jeanine Ursinus; Hans L Zaaijer; Herman Kuiper; Joppe W Hovius
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

8.  Serodiagnosis of Lyme borreliosis-is IgM in serum more harmful than helpful?

Authors:  Henrik Hillerdal; Anna J Henningsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-07       Impact factor: 3.267

Review 9.  Control of Lyme borreliosis and other Ixodes ricinus-borne diseases.

Authors:  Hein Sprong; Tal Azagi; Dieuwertje Hoornstra; Ard M Nijhof; Sarah Knorr; M Ewoud Baarsma; Joppe W Hovius
Journal:  Parasit Vectors       Date:  2018-03-06       Impact factor: 3.876

10.  Modified interpretation criteria significantly improve performance of commercially available confirmatory assays for the serodiagnosis of Lyme borreliosis: a case-control study with clinically defined serum samples.

Authors:  Ulrike Hauser
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.